AC Immune SA announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial of ACI-7104.056, its anti-alpha-synuclein active immunotherapy for early Parkinson’s disease. These results were observed after six months of treatment.
The data showed no serious adverse events considered related to the study drug in the blinded, pooled active and placebo groups. The most common adverse events reported were mild and transient injection site reactions and headaches, indicating a favorable safety profile.
Treatment with ACI-7104.056 induced an increase in anti-alpha-synuclein antibodies on average over 20-fold higher than the placebo background level after four immunizations. This demonstrates a robust and boostable antibody response against the target antigen.
AC Immune expects to share further updates later in 2025, including pharmacodynamic and biomarker data, which may inform the decision to initiate Part 2 of the VacSYn trial with up to 150 patients. These findings reinforce the potential of ACI-7104.056 as a leading candidate for Parkinson's disease treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.